Vuno
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Vuno makes artificial-intelligence software that helps doctors analyse medical images, such as X-rays, CT scans, MRI scans, and retinal photographs, as well as biological signals, to support diagnosis and patient-outcome prediction.
Its products are used in clinical settings, with hospitals and healthcare providers as its primary customers. Listed on KOSDAQ, Korea's tech-focused stock exchange, the company describes itself as a pioneer in commercialising deep-learning technology within Korea's medical-device market, having introduced the country's first approved AI medical-device product.
Summary is AI-generated and may contain errors · figures from DART filings
Vuno in five facts
What does Vuno do?
Vuno makes artificial-intelligence software that helps doctors analyse medical images, such as X-rays, CT scans, MRI scans, and retinal photographs, as well as biological signals, to support diagnosis and patient-outcome prediction.
Where is Vuno listed and in which sector?
Vuno (Korean name: 뷰노) trades under KRX code 338220 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Information Technology sector, Software.
How large is Vuno?
Its market capitalisation was US$66.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Vuno's latest annual revenue and operating profit?
For fiscal year 2025, Vuno reported revenue of US$26.3M, an operating loss of US$3.7M and a net loss of US$4.4M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 34.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Securities registration statement (equity)Oct 15
- [Amended] Material event report (rights offering)
Vuno updated the terms of a new share issuance to raise US$23.5M, about 33.1% of its market value.
Capital raise · Oct 15 · 3 versions - Executives/major shareholders' securities trading planOct 6
- DisclosureOct 6
- [Amended] Securities registration statement (equity)Sep 29
- [Amended] Securities registration statement (equity)Sep 29
- Executives/major shareholders' securities trading planSep 22
- Report on securities held by executives/major shareholdersSep 22
- [Amended] Securities registration statement (equity)Sep 11
- Report on large shareholdings (5% rule) (standard)Sep 4
- Completion report on merger, etc. (asset transfer)
Vuno reports that the transfer of VUNO Med-BoneAge assets to My Herb Co., Ltd. for US$1.99M, originally approved on 2025-09-10, was completed on 2026-09-04 with full payment of the balance, after delays in the asset-transfer procedures.
M&A · Sep 4 - Early redemption of convertible bonds (incl. overseas CBs)
Vuno acquired the entire remaining face amount of US$6.39M of its 2nd series perpetual convertible bonds (conversion price US$14.52/share, maturing 2054-03-26) before maturity for US$6.75M, following the issuer's exercise of its early redemption right; the bonds will be cancelled from electronic registration.
Capital raise · Aug 26 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Feb 26
- Material event report (convertible bonds)
Vuno disclosed convertible bonds to raise US$6.92M, about 11.0% of its market value.
Capital raise · Feb 12 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Vuno reported consolidated results for FY2025: revenue of US$24.1M (+34.7% year on year), an operating loss of US$3.41M and a net loss of US$4M.
Earnings · Feb 4